ROSIGLITAZONE EFFCT ON ADIPCYTE-DERIVD CYTOKINES IN NONDIABTC PTS W/METABLC SYND

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者的研究机构。 这项研究的目的是确定罗格列酮，一种“胰岛素增敏剂”，是否会有利地改变代谢综合征患者的脂肪细胞蛋白质。 代谢综合征是一系列健康风险的集合，这些风险增加了一个人未来患2型糖尿病和心血管疾病的机会。 由于代谢综合征在美国正以惊人的速度增加，因此确定改变该人群疾病进展的替代方法至关重要。 罗格列酮可能有助于改变脂肪细胞产生的蛋白质的数量。 这可能会提高身体使用胰岛素的能力，并影响代谢综合征的某些部分。 目前，使用药物，如罗格列酮，不是代谢综合征患者的标准治疗。 我们的研究是早期的一步，看看罗格列酮是否对代谢综合征患者有益。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine if rosiglitazone, an 'insulin sensitizer', will favorably alter fat cell proteins in people with the metabolic syndrome. The metabolic syndrome is a collection of health risks that increase a person's chance for the future development of type 2 diabetes and cardiovascular disease. Because the metabolic syndrome is increasing at alarming rates in the United States, identification of alternative ways to alter disease progression in this population is essential. Rosiglitazone may be helpful in altering the amount of proteins made by the fat cells. This may improve the body's ability to use insulin and impact some of the parts of the metabolic syndrome. Currently, use of medications, like rosiglitazone, is not standard of care in people who have the metabolic syndrome. Our study is an early step to see if rosiglitazone will be beneficial in people who have the metabolic syndrome.